Lung cancer: open trials in Czechia

34 open trials have a site in Czechia. Registry data; only the trial team decides who can take part.

NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Trial Treatment · Phase 3 · Amgen
Fakultni nemocnice Brno, Brno · Masarykuv Onkologicky Ustav, Brno-Stred · Fakultni nemocnice Hradec Kralove, Hradec Králové · University Hospital Olomouc, Olomouc · Fakultni Nemocnice Plzen, Plzen 3
Registry updated 2026-11-06
NCT07144280
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · Pfizer
Fakultni nemocnice Brno, Brno · Nemocnice AGEL Nový Jičín a.s., Nový Jičín · University Hospital Olomouc, Olomouc · Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava · Fakultni Nemocnice Motol a Homolka, Prague · Všeobecná fakultní nemocnice v Praze, Praha 2
Registry updated 2026-11-05
NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava · Fakultni nemocnice Bulovka, Prague
Registry updated 2026-11-04
NCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 3 · Bayer
Masarykuv Onkologicky Ustav, Brno-Stred · Nemocnice AGEL Nový Jičín a.s., Nový Jičín · Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava · Krajska Nemocnice T Bati a.s., Zlin
Registry updated 2026-11-04
NCT06890598
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Eli Lilly and Company
Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava · Fakultni nemocnice Bulovka, Prague
Registry updated 2026-11-04
2022-502959-54-00
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
Trial Treatment · Phase 3 · Dizal Pharmaceutical Co. Ltd.
Vitkovicka Nemocnice a.s. - Plicni oddeleni, Ostrava
Registry updated 2026-11-03
NCT03340506
Dabrafenib and/or Trametinib Rollover Study
Trial Treatment · Phase 4 · Novartis Pharmaceuticals
Fakultni nemocnice Brno, Brno · Fakultni Nemocnice Motol a Homolka, Prague
Registry updated 2026-11-03
NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
University Hospital Olomouc, Olomouc · Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava · Multiscan s.r.o., Pardubice · Vseobecna Fakultni Nemocnice V Praze, Prague 2
Registry updated 2026-11-03
NCT07230691
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
Research · Janssen Research & Development, LLC
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · Fakultni nemocnice Olomouc, Olomouc · Fakultni Thomayerova nemocnice, Prague
Registry updated 2026-11-03
NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Trial Treatment · Phase 2/3 · Mirati Therapeutics Inc.
Multiscan s.r.o., Hořovice · Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava
Registry updated 2026-10-30
NCT04928846
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Trial Treatment · Phase 3 · AbbVie
Masarykuv Onkologicky Ustav, Brno-Stred · Nemocnice AGEL Nový Jičín a.s., Nový Jičín
Registry updated 2026-10-29
NCT06422143
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Masarykuv Onkologicky Ustav, Brno-Stred · University Hospital Olomouc, Olomouc · Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava · Multiscan s.r.o., Pardubice
Registry updated 2026-10-29
NCT04557449
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Trial Treatment · Phase 1/2 · Pfizer
University Hospital Olomouc, Olomouc · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-10-28
NCT06914128
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Trial Treatment · Phase 1/2 · Bayer
Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP), Brno · Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc
Registry updated 2026-10-28
NCT07472517
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Trial Treatment · Phase 3 · Boehringer Ingelheim
University Hospital Olomouc, Olomouc · Fakultni Thomayerova nemocnice, Prague
Registry updated 2026-10-28
NCT07063745
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Trial Treatment · Phase 2/3 · Bristol-Myers Squibb
Fakultni nemocnice Hradec Kralove, Hradec Králové · University Hospital Olomouc, Olomouc · Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava
Registry updated 2026-10-23
NCT07361510
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Trial Treatment · Phase 3 · Bristol-Myers Squibb
Fakultni nemocnice Hradec Kralove, Hradec Králové · University Hospital Olomouc, Olomouc · Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava · Fakultni Nemocnice Plzen, Plzen 3
Registry updated 2026-10-23
2025-522818-23-00
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
Trial Treatment · Phase 3 · Zai Lab (US) LLC
Multiscan s.r.o., Hořovice · University Hospital Olomouc, Olomouc · Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava · Fakultni nemocnice Kralovske Vinohrady, Prague
Registry updated 2026-10-19
NCT06162221
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Trial Treatment · Phase 1/2 · Revolution Medicines, Inc.
Nemocnice AGEL Nový Jičín a.s., Nový Jičín
Registry updated 2026-10-19
NCT07218146
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Trial Treatment · Phase 3 · Zai Lab (Shanghai) Co., Ltd.
Nemocnice Horovice, Hořovice · Nemocnice AGEL Ostrava-Vitkovice a. s., Vítkovice
Registry updated 2026-10-16
NCT06312137
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Masarykuv Onkologicky Ustav, Brno-Stred · Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava
Registry updated 2026-10-15
NCT07625644
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Trial Treatment · Phase 3 · SystImmune Inc.
Nemocnice České Budějovice, a.s., České Budějovice · Nemocnice Agel Vítkovice, Ostrava · Fakultní nemocnice Ostrava (FN Ostrava), Ostrava-Poruba
Registry updated 2026-10-15
NCT06646276
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Trial Treatment · Phase 3 · Bristol-Myers Squibb
Masarykuv Onkologicky Ustav, Brno-Stred · University Hospital Olomouc, Olomouc · Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava · Fakultni Thomayerova nemocnice, Prague 4
Registry updated 2026-10-13
NCT07222566
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Trial Treatment · Phase 3 · Pfizer
Fakultni nemocnice Brno, Brno · Nemocnice AGEL Nový Jičín a.s., Nový Jičín · University Hospital Olomouc, Olomouc · Nemocnice AGEL Ostrava - Vitkovice a.s., Ostrava · Multiscan s.r.o., Pardubice · Fakultni Thomayerova nemocnice, Prague · Fakultni Nemocnice Motol a Homolka, Prague
Registry updated 2026-10-08
NCT06216301
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Trial Treatment · Phase 3 · NovoCure GmbH
Fakultni nemocnice Olomouc FNOL, Olomouc · Nemocnice Agel Ostrava-Vitkovice / Agel Ostrava-Vitkovice Hospital, Ostrava · General University Hospital in Prague, Prague
Registry updated 2026-10-06

All Lung cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error